1 / 1

TITULO Autores:

LOGO. TITULO Autores: . LOGO. Procedencia y correos electrónicos . ANTECEDENTES:

tasya
Télécharger la présentation

TITULO Autores:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LOGO TITULO Autores: LOGO Procedencia y correos electrónicos ANTECEDENTES: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx IMAGEN O GRAFICA IMAGEN O GRAFICA XXXX. 1 XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXX 4. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX JUSTIFICACIÓN: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx IMAGEN, TABLA O GRAFICA IMAGEN, GRAFICA O TABLA XXXX 2. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXX CONCLUSIONES: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx XXXX. 1 XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX HIPOTESIS: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx RESULTADOS: OBJETIVO: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx IMAGEN, TABLA O GRAFICA METODOLOGÍA: XXXXXXX XXXXXXX XXXXX • BIBLIOGRAFIA: • P. Calabresi y A. B. Chabner. 2001. “Fármacos antineoplásicos” en: Goodman & Gilman. Las bases Farmacológicas de la Terapéutica. 10ª Edición. McGraw-Hill Interamericana. 1405-1475. • E Groninger, MT de Boer, P Koopmans, D Uges, W Sluiter, A Veerman W, Kamps, S de Graaf. 2005. “Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG)”. Europ J Cancer; 41:98-103. • G Lönnerholm, BM Frost, J Abrahamsson, M Behrendtz, A Castor, E Forestier, M Heyman, DRA Uges and SSN de Graaf. 2008. “Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia”. Br J Haematoy; 142(4): 616-621. • D Levêque and F Jehl. 2007. “Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids”. J ClinPharmacol; 47:579-588. • DCh Scripture y DW Figg. 2006. “Drug interactions in cancer therapy”. Nature Reviews; 6:546-558. • JB Dennison, P Kulanthaivel, RJ Barbuch, JL Renbarger, WJ Ehlhardt, SD Hall. 2006. “Selective Metabolism of Vincristine in Vitro by CYP3A5. Drug MetabolDisp”; 34:1317-1327. • JB Dennison, MA Mohutsky, RJ Barbuch, SA Wrighton, SD Hall. 2008.“Apparent High CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes”JPharmacol ExpTher;1-35 • D Levêque and F Jehl. 2007. “Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids”. J ClinPharmacol; 47:579-588. • CCO. Cancer Care Ontario. 2006/2007. “Vincristine. CCO Formulary”. Revised. • JE Estlin, M Ronghe, AAG Burke, MS Yule. 2000. “The Clinical and Cellular Pharmacology of Vincristine, Corticosteroides, L-asparaginase, Anthracyclines and Cyclophosphamide in Relation to Childhood Acute Lymphoblastic Leukaemia”. Br J Haematol; 110:780-790. XXXXX XXX. 3 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX 0 XXXXX 24 XXXXXXXXXXXXXX IMAGEN, GRAFICA O TABLA XXXXXXXX XXXXXXXXX XXXXXXXXXX grafica o imagen XXX1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXX horas

More Related